SEARCH

A VACCINE THAT WORKS FAST AND

GOES THE DISTANCE

Producers and veterinarians around the world know what laboratory and on-farm studies have proven. Ingelvac CircoFLEX® goes to work early and keeps working through finishing.

EARLIEST ONSET OF IMMUNITY (2 WEEKS)

With onset of immunity within two weeks, Ingelvac CircoFLEX is the only PCV2 vaccine that protects pigs as early as five weeks of age and lasts through finishing.1

  • Earliest possible protection currently available
  • Healthy piglets are less susceptible to other diseases, such as PRRS, Mycoplasma hyopneumoniae and ileitis

OVERRIDES MATERNAL IMMUNITY

Ingelvac CircoFLEX gives you the option and convenience of vaccinating at weaning and has been demonstrated to override maternal immunity in four field trials.2,3,4,5 

  • Licensed for pigs 3 weeks of age or older
  • Convenience of vaccinating at weaning
  • Vaccination at weaning provides effective immunization for both the early (3 wks of age) and late (grow-finish) forms of PCVAD (circovirus)

DURATION OF IMMUNITY (THROUGH FINISHING)

The technology contained in our Purified Circovirus Antigen (PCA™) combined with our revolutionary ImpranFLEX™ adjuvant, creates fast-acting and long-lasting immunity. The Free PCA is immediately recognized by the immune system. The Cross-linked PCA creates a slow-release depot effect.

  • Provides protection through critical period in grow-finish
  • Fewer injections; no booster required
  • Less stress on pigs and on people

CLINICAL RESULTS

Field studies confirm that Ingelvac CircoFLEX can dramatically improve performance at both the clinical and subclinical stages.

A recent US field trial in a clinical setting found significant reductions in mortality, cull, and PCVAD diagnosis rates, as well as a reduction in viral load and a marked increase in ADG and final body weight.1

SUBCLINICAL RESULTS

Studies have shown significant benefits in herds not displaying clinical signs of PCVAD. Vaccinated pigs showed overall better performance, with increased final market weights and a significant improvement in percentage of prime pigs marketed. Improvements in carcass traits were also observed.6


Click here to download this webpage as a PDF.

References
1. Cline, G., Wilt, V., Diaz, E., Efficacy of Ingelvac CircoFLEX in pigs vaccinated at 3 and 6 weeks of age in a PRRS and Mycoplasma hyopneumoniae-negative production system, Leman Conference 2007.
2. Ritzmann, M., et al., Lack of interference with maternal immunity and reduction of viremia in PCV2 vaccinated pigs, IPVS 2008.
3. Edler, R., et al., Effiacy of PCV2 vaccination of pigs, dams, or both on pig performance, Leman Conference 2008.
4. Grosse Liesner, B., et al., Efficacy of Ingelvac CircoFLEX in face of maternal antibodies in a field trial in France, Leman Conference 2008.
5. Desrosiers, R., et al., Use of a one-dose subunit vaccine to prevent losses associated with porcine circovirus type 2, Journal of Swine Health and Production, May and June 2009.
6. King, D., Biologic benefits of controlling subclinical PCVAD with vaccination, AASV, 2008.